ERBB2 and breast neoplasm: In addition, adjuvant dual HER-2 blockade using Trastuzumab and Lapatinib (in combination with anthracycline/taxane–based chemotherapy) significantly increased the rate of the pathological complete response (pCR) of HER-2 positive primary breast tumors to over 50% compared to Trastuzumab provided alone [37].